Modulation of immune cell infiltrate with sunitinib to improve anti-PD1 therapy in preclinical tumor model by unknown
POSTER PRESENTATION Open Access
Modulation of immune cell infiltrate with
sunitinib to improve anti-PD1 therapy in
preclinical tumor model
Patricia Rayman1*, C Marcela Diaz-Montero2, Yu Yang2, Brian Rini2, Paul Elson2, James Finke1
From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
National Harbor, MD, USA. 4-8 November 2015
Combined therapy using the checkpoint blockade anti-
PD1 antibody and the TKI, sunitinib, has been investigated
in metastatic renal cell carcinoma (mRCC). Here we
examined the impact of sunitinib plus anti-PD1 therapy
on tumor growth in the renal cell carcinoma mouse model
RENCA. Treatment was initiated on day 5 after implanta-
tion of tumor (0.5 million) subcutaneously and consisted
of oral gavage with sunitinib (40mg/kg) given daily for 21
days while anti-PD-1 antibody (BioXcell) was given i.p
(200ug/100ul) twice a week for three 3 weeks. Treatment
groups included sunitinib, anti-PD-1 and both agents
while untreated RENCA bearing mice served as controls.
Because sunitinib is so effective at reducing tumor growth
in the RENCA model, analysis of immune changes in the
tumor were assessed in mice with larger and more estab-
lished tumors (treatment was initiated on day 17, given at
the same doses and methods for 7 days). Sunitinib consis-
tently induced a 54% reduction in tumor volume if treat-
ment started on day 17, and >90% if started Day 5, which
was not sustained once drug therapy ended. Anti-PD-1
antibody monotherapy caused variable reduction in tumor
volume and modestly prolonged survival but only the
combination therapy was effective at inducing complete
tumor regression in the mice. FACS analysis of single cell
suspension after tumor digest revealed that sunitinib
alone significantly reduced granulocytic (CD11b+Ly6G
+Ly6Clow) and monocytic (CD11b+Ly6G-Ly6Chi) mye-
loid derived suppressor cells (MDSC) by 52% and 68%,
respectively. With combination treatment MDSC were
reduced by 74% (G-MDSC) and 94% (M-MDSC) respec-
tively from untreated tumors. In contrast anti-PD-1 anti-
body monotherapy had no effect on MDSCs levels. FACS
studies further revealed sunitinib monotherapy caused an
immune cell infiltrate that was composed predominately
of CD8+ T cells (38%) compared to PD-1 antibody treat-
ment (6%). A high percentage of the CD8+ T cells from
the sunitinib and sunitinib/anti-PD1-treated mice
expressed CD107a (a lysomal-associated membrane pro-
tein known to be involved in lytic destruction of tumor
target cells) (44% and 60%), compared to untreated and
anti-PD1 treated mice (3% and 7% respectively). Combina-
tion with sunitinib and PD-1 antibody treatment not only
increases the infiltrate of CD8+ T cells but also their
frequency of actively cytolytic CD8+ T cells as evidenced
by their increased frequency of CD107a expressing cells,
suggesting a reverse of immunosuppression by MDSCs.
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